Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease
INTRODUCTION Phase 3 trials using the anti‐amyloid antibodies aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease dementia were heterogeneous in respect to statistical significance of effects. However, heterogeneity of results has not yet direc...
Saved in:
Published in | Alzheimer's & dementia : translational research & clinical interventions Vol. 10; no. 1; pp. e12454 - n/a |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley and Sons Inc
01.01.2024
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | INTRODUCTION
Phase 3 trials using the anti‐amyloid antibodies aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease dementia were heterogeneous in respect to statistical significance of effects. However, heterogeneity of results has not yet directly be quantified.
METHODS
We used Bayesian random effects meta‐analysis to quantify evidence for or against a treatment effect, and assessed the size of the effect and its heterogeneity. Data were extracted from published studies where available and Web based data reports, assuming a Gaussian data generation process.
RESULTS
We found moderate evidence in favor of a treatment effect (Bayes factor = 13.2). The effect was moderate to small with −0.33 (95% credible interval −0.54 to −0.10) points on the Clinical Dementia Rating – Sum of Boxes (CDR‐SB) scale. The heterogeneity parameter was low to moderate with 0.21 (0.04 to 0.45) CDR‐SB points.
DISCUSSION
Heterogeneity across studies was moderate despite some trials reaching statistical significance, while others did not. This suggests that the negative aducanumab and gantenerumab trials are in full agreement with the expected effect sizes. |
---|---|
ISSN: | 2352-8737 2352-8737 |
DOI: | 10.1002/trc2.12454 |